Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bi-functional antiplatelet aggregation medicine and application thereof

An anti-platelet aggregation, dual-function technology, applied in the field of medicine, can solve the problems that have not yet been

Inactive Publication Date: 2012-08-01
FUDAN UNIV
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

To date, there is no information about having P2Y at the same time 12 Drugs with Dual Functions of Receptor Antagonism and Phosphodiesterase Inhibition

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bi-functional antiplatelet aggregation medicine and application thereof
  • Bi-functional antiplatelet aggregation medicine and application thereof
  • Bi-functional antiplatelet aggregation medicine and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1. Inhibition of Phosphodiesterase Activity by BF061

[0021] The purpose of this example is to demonstrate the anti-phosphodiesterase activity of BF061.

[0022] In this example, phosphodiesterase was purified from human platelets, and the enzyme reaction was performed in 200 μL of PBS buffer (137 mM NaCl, 2.7 mM KCl, 8.8 mM NaCl 2 HPO 4 , 1.5 mM KH 2 PO 4 , 1 mM CaCl 2 , 1 mM MgCl 2 , 10 μM cAMP, pH 7.4), the substrate is 25 μM cAMP (sigma company), the system contains 10 μL of phosphodiesterase, and the phosphodiesterase is calculated by measuring the residual substrate concentration after 30 minutes of enzyme reaction activity. The residual substrate concentration was determined by high-pressure liquid chromatography with a C18 column (Kromasil 4.6 × 150 mm, Eka-chemicals, Bohns, Sweden). The results are shown in Table 1, showing that BF061 has obvious inhibitory effect on phosphodiesterase activity.

[0023]

[0024] Table 1: BF061 inhibits phosp...

Embodiment 2

[0026] Example 2. P2Y of BF061 12 receptor antagonism

[0027] The purpose of this example is to prove that BF061 has P2Y 12 Receptor antagonism.

[0028] In this example, the ligands ADP and P2Y 12 The binding force between the receptors was determined by atomic force microscopy (Asylum Research, Santa Barbara, CA). The probe was pre-coated in ADP (500 ng / μL, 20 μL) overnight, and finally ADP was coupled to the probe. P2Y 12 The receptors are expressed in CHO-K1 cells. The conditions for the determination of the binding force between the probe and the cell surface receptors are: pressure velocity 3 μm / s, contact time 0.2 s, contact force 100 pN, cantilever correction coefficient about 20 pN / nm. The results are shown in Table 2. After BF061 treatment, the ligands ADP and P2Y 12 The binding force between receptors is significantly weakened, showing that BF061 has obvious P2Y 12 Receptor antagonism.

[0029]

[0030] Table 2: BF061 antagonizes P2Y 12 Receptors b...

Embodiment 3

[0032] Example 3. Inhibitory effect of BF061 on ADP-induced human platelet aggregation

[0033] The purpose of this example is to prove that BF061 can inhibit ADP-induced human platelet aggregation

[0034] Preparation of platelets: Platelets were obtained from healthy volunteers who signed the informed consent form. Volunteers had not taken any antiplatelet drugs such as aspirin and clopidogrel within 20 days before blood collection. Anticoagulant ACD (85 mmol L -1 sodium citrate, 71.38 mmol L -1 citric acid, and 27.78 mmol L -1 glucose). Centrifuge at 300 x g for 20 minutes to obtain platelet-rich plasma, take the supernatant and centrifuge at 900 x g for 10 minutes to obtain platelets, and finally resuspend in Tyrode’s buffer (138 mmol L -1 NaCl, 2.7 mmol L -1 KCl, 2 mmol L -1 MgCl 2 , 0.42 mmol L -1 NaH 2 PO 4 , 5 mmol L -1 glucose, 10 mmol L -1 HEPES, 0.2% bovine serum albumin, and 0.02 unit mL -1 apyrase, pH 7.4), to obtain washed platelets, the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention, belonging to the technical field of medicine, relates to a bi-functional anti-platelet aggregation medicine and an application of the medicine in preventing and treating arterial tlirombotic diseases. The medicine of the invention has both a P2Y12 receptor antagonist property and a phosphodiesterase inhibitory activity. The results of in vivo and in vitro anti-platelet aggregation activity experiments of the medicine provide the anti-platelet mechanism of the medicine, the structural formula and anti-platelet mechanism of the medicine are different from those of known anti-platelet medicines, aspirin, Clopidogrel, Prasugrel, Cilostazol, and platelet and fibrinogen receptor antagonist. The medicine of the invention has good inhibition effect to various platelet aggregation induced by agonists. The results of mice in vivo experiment models of arterial thrombosis show that the medicine of the invention has significantly similar antithrombotic activity with Clopidogrel and non-obvious side effect of hemorrhage. The medicine of the invention can be used as antithrombotic medications for treating coronary heart disease, apoplexy and other arterial tlirombotic diseases.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to an antiplatelet medicine and its application in preventing and treating arterial thrombosis diseases. Background technique [0002] With the improvement of living standards, stroke, coronary heart disease and other arterial thrombotic diseases have become the number one killer threatening the health of people in our country and developed countries. Studies have shown that intravascular thrombus formation caused by abnormal activation of platelets is the pathological basis of arterial thrombosis coronary heart disease and stroke, so antiplatelet drugs that inhibit platelet activation have become the main means of prevention and treatment of such diseases. Relevant studies have shown that the curative effect of antiplatelet drugs on coronary heart disease and stroke is affirmative, but practice shows that the therapeutic effect of coronary heart disease and stroke is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07H19/167A61K31/7076A61P7/02A61P9/10
CPCA61K31/7076C07H19/167A61P7/02A61P9/10
Inventor 丁忠仁胡亮张思杜洪光
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com